P279 Interest of serum calprotectin in inflammatory bowel disease (IBD): a prospective monocentric study
T. Di Bernardo*1, A. Haccourt1, P. Veyrard1, E. Del Tedesco1, J. M. Phelip1, N. Williet1, S. Paul1, X. Roblin1
1Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France
Faecal calprotectin (FC) is the most effective non-invasive biomarker for the diagnosis and monitoring of inflammatory bowel diseases (IBD). It is a major marker in the ‘Treat to Target’ strategy. However, in clinical practice, the faecal sample appears to be restrictive for patients. The aim of our study was to evaluate the diagnostic performance of serum calprotectin (SC) to predict clinical remission (CR) and mucosal healing (MH) in IBD patients.
It was a prospective monocentric study. We have consecutively included any patient with either ulcerative colitis (UC) or Crohn's disease (CD) and followed in our IBD centre. Exclusion criteria were: inflammatory rheumatism,
From June 2017 to June 2018, 82 patients (60.2% CD, sex ratio M/F = 0.74, mean age 42.19 ± 15.4 years) were included and we performed 123 SC assays. Of the 123 assays of SC, 87 (70.7%) were performed in patients with CR. With respect to the prediction of CR, SC had an area under the curve (AUC) of 0.67. A cut-off value of 5.3 mg/ml predicted a clinical remission with a sensitivity (Se) of 65.6%, a specificity (Sp) of 67.6%, conferring diagnostic performance not inferior to other biomarkers such as CRP (
This study has shown that SC is a predictive biomarker of CR and MH in IBD patients. This biomarker was not inferior to other biomarkers in terms of prediction. Further studies involving more patients are needed to confirm the future role of SC in IBD management.